Psoriasis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Psoriasis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


Psoriasis drug manufacturers set to benefit from the development of novel biologics, while high treatment costs and lack of awareness remain challenges.

The global psoriasis drugs market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7% and reach a valuation of US$ 21.48 billion by 2031, according to a recent report. In 2024, worldwide sales of psoriasis drugs already amounted to approximately US$ 13 billion.

Key Opportunities for Psoriasis Drug Manufacturers

Novel Biologics to Carry Market Growth Forward

The treatment landscape for psoriasis has evolved significantly over the years, with various therapies available to manage the condition's symptoms. However, manufacturers are increasingly focusing on the development of novel biologics, such as tumor necrosis factor and interleukin, which offer the potential for long-term efficacy with minimal side effects. These advancements are expected to drive growth in the psoriasis drugs market as an alternative to conventional treatments.

Furthermore, the rising number of identified cases of psoriasis worldwide has spurred research and development efforts to create new treatment options. Strong product pipelines and increasing regulatory approvals for drugs like Stelara and Cimzia are contributing to the growth of psoriasis drug consumption in many regions.

Factors Restraining Demand for Psoriasis Drugs

High Cost of Psoriasis Treatment Impeding Market Expansion

One of the major factors hindering the demand for psoriasis drugs is the high cost associated with treatment. Patients often face substantial medical expenses related to psoriasis, and this cost is further exacerbated when comorbidities are present.

Additionally, the high expenses incurred during the development of novel biological drugs, including regulatory approvals and patent filings, can limit market growth. Lack of awareness about psoriasis and its associated comorbidities also hampers market expansion, leading to under-diagnosis and ineffective therapy.

Country-wise Insights

U.S. Psoriasis Drugs Market Leading Global Industry

The United States is the largest market for psoriasis drugs globally, dominating the North American region. It is expected to continue experiencing significant growth due to a high prevalence of psoriasis, increased adoption of prescribed dermatological products for psoriasis management, a well-established healthcare infrastructure, the presence of key psoriasis medication manufacturers, favorable government initiatives, and reimbursement policies.

U.K. Driving Europe Psoriasis Drugs Market Growth

In Europe, the United Kingdom (U.K.) is a lucrative market for psoriasis drugs, with a projected growth rate of 7.1% over the forecast period. This growth is driven by breakthrough therapies for plaque psoriasis treatment, growing public awareness, increased research and development efforts for psoriasis treatment, and approvals for new drugs. For example, the University of Manchester and Salford Royal NHS Foundation Trust conducted studies on Bimekizumab, demonstrating its efficacy in treating moderate to severe psoriasis, which received approval for use in adults.

China – Emerging Market for Psoriasis Drugs

China is an emerging market to watch for manufacturers of psoriasis drugs. It holds a significant share in the Asia-Pacific, East Asia, and Japan (APEJ) psoriasis drugs market. China is expected to expand at a CAGR of 9.4% during the forecast period due to unmet clinical demands among patients, rising per capita income, increased awareness for early diagnosis, and improved access to high-quality therapy. The growth of the psoriasis treatment market in China is also attributed to key manufacturers establishing a presence in the country. For example, Novartis obtained approval in China for Cosentyx® (secukinumab) for treating moderate to severe plaque psoriasis, including in pediatric patients.

Impact of COVID-19 on the Market

The COVID-19 pandemic initially had a negative impact on psoriasis drug sales, as patients were advised to suspend or reschedule immunosuppressant medications. However, researchers later provided guidelines for patient care and psoriasis treatment during the pandemic, contributing to the steady growth of the market.

Competitive Analysis

Leading psoriasis drug manufacturers are focused on launching new products and promoting their brands to gain a larger market share. Marketing strategies, approvals, and product launches are critical components of their growth strategies. These companies are also working on developing value chains for major regional markets and creating new psoriasis drugs and long-term solutions.

Key Companies Profiled
• Janssen Biotech, Inc.
• Novartis International Ltd.
• Amgen Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Ltd.
• Merck & Co, Inc.
• AbbVie Inc.
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• Sun Pharmaceutical Industries Ltd.

Key Segments Covered in Psoriasis Drugs Industry Research

Psoriasis Drugs Market by Product:
• Topical Psoriasis Drugs
• Oral Psoriasis Drugs
• Injectable Psoriasis Drugs

Psoriasis Drugs Market by Drug Class:
• Interleukin Inhibitors
• Corticosteroids
• Anti-inflammatory
• Tumor Necrosis Factor Inhibitors

Psoriasis Drugs Market by Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• e-Commerce

Psoriasis Drugs Market by Indication:
• Guttate Psoriasis
• Inverse Psoriasis
• Pustular Psoriasis
• Erythrodermic Psoriasis
• Plaque Psoriasis

Psoriasis Drugs Market by Region:
• North America Psoriasis Drugs Market
• Latin America Psoriasis Drugs Market
• Europe Psoriasis Drugs Market
• South Asia Psoriasis Drugs Market
• East Asia Psoriasis Drugs Market
• Oceania Psoriasis Drugs Market
• Middle East and Africa (MEA) Psoriasis Drugs Market

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global Psoriasis Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Psoriasis Drugs Market Outlook, 2018 – 2031
3.1. Global Psoriasis Drugs Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Topical Psoriasis Drugs
3.1.1.2. Oral Psoriasis Drugs
3.1.1.3. Injectable Psoriasis Drugs
3.2. Global Psoriasis Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Interleukin Inhibitors
3.2.1.2. Corticosteroids
3.2.1.3. Anti-inflammatory
3.2.1.4. Tumor Necrosis Factor Inhibitors
3.3. Global Psoriasis Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. Guttate Psoriasis
3.3.1.2. Inverse Psoriasis
3.3.1.3. Pustular Psoriasis
3.3.1.4. Erythrodermic Psoriasis
3.3.1.5. Plaque Psoriasis
3.4. Global Psoriasis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
3.4.1. Key Highlights
3.4.1.1. Hospital Pharmacies
3.4.1.2. Retail Pharmacies
3.4.1.3. e-Commerce
3.5. Global Psoriasis Drugs Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Psoriasis Drugs Market Outlook, 2018 – 2031
4.1. North America Psoriasis Drugs Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Topical Psoriasis Drugs
4.1.1.2. Oral Psoriasis Drugs
4.1.1.3. Injectable Psoriasis Drugs
4.2. North America Psoriasis Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Interleukin Inhibitors
4.2.1.2. Corticosteroids
4.2.1.3. Anti-inflammatory
4.2.1.4. Tumor Necrosis Factor Inhibitors
4.3. North America Psoriasis Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. Guttate Psoriasis
4.3.1.2. Inverse Psoriasis
4.3.1.3. Pustular Psoriasis
4.3.1.4. Erythrodermic Psoriasis
4.3.1.5. Plaque Psoriasis
4.4. North America Psoriasis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
4.4.1. Key Highlights
4.4.1.1. Hospital Pharmacies
4.4.1.2. Retail Pharmacies
4.4.1.3. e-Commerce
4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Psoriasis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
4.5.1.2. U.S. Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
4.5.1.3. U.S. Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
4.5.1.4. U.S. Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
4.5.1.5. Canada Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
4.5.1.6. Canada Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
4.5.1.7. Canada Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
4.5.1.8. Canada Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Psoriasis Drugs Market Outlook, 2018 – 2031
5.1. Europe Psoriasis Drugs Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Topical Psoriasis Drugs
5.1.1.2. Oral Psoriasis Drugs
5.1.1.3. Injectable Psoriasis Drugs
5.2. Europe Psoriasis Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Interleukin Inhibitors
5.2.1.2. Corticosteroids
5.2.1.3. Anti-inflammatory
5.2.1.4. Tumor Necrosis Factor Inhibitors
5.3. Europe Psoriasis Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Guttate Psoriasis
5.3.1.2. Inverse Psoriasis
5.3.1.3. Pustular Psoriasis
5.3.1.4. Erythrodermic Psoriasis
5.3.1.5. Plaque Psoriasis
5.4. Europe Psoriasis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. Hospital Pharmacies
5.4.1.2. Retail Pharmacies
5.4.1.3. e-Commerce
5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Psoriasis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
5.5.1. Key Highlights
5.5.1.1. Germany Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.2. Germany Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
5.5.1.3. Germany Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
5.5.1.4. Germany Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.5.1.5. U.K. Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.6. U.K. Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
5.5.1.7. U.K. Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
5.5.1.8. U.K. Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.5.1.9. France Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.10. France Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
5.5.1.11. France Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
5.5.1.12. France Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.5.1.13. Italy Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.14. Italy Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
5.5.1.15. Italy Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
5.5.1.16. Italy Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.5.1.17. Turkey Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.18. Turkey Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
5.5.1.19. Turkey Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
5.5.1.20. Turkey Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.5.1.21. Russia Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.22. Russia Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
5.5.1.23. Russia Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
5.5.1.24. Russia Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.5.1.25. Rest of Europe Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.26. Rest of Europe Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
5.5.1.27. Rest of Europe Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
5.5.1.28. Rest of Europe Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Psoriasis Drugs Market Outlook, 2018 – 2031
6.1. Asia Pacific Psoriasis Drugs Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Topical Psoriasis Drugs
6.1.1.2. Oral Psoriasis Drugs
6.1.1.3. Injectable Psoriasis Drugs
6.2. Asia Pacific Psoriasis Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Interleukin Inhibitors
6.2.1.2. Corticosteroids
6.2.1.3. Anti-inflammatory
6.2.1.4. Tumor Necrosis Factor Inhibitors
6.3. Asia Pacific Psoriasis Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Guttate Psoriasis
6.3.1.2. Inverse Psoriasis
6.3.1.3. Pustular Psoriasis
6.3.1.4. Erythrodermic Psoriasis
6.3.1.5. Plaque Psoriasis
6.4. Asia Pacific Psoriasis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. Hospital Pharmacies
6.4.1.2. Retail Pharmacies
6.4.1.3. e-Commerce
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Psoriasis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
6.5.1. Key Highlights
6.5.1.1. China Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.2. China Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
6.5.1.3. China Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
6.5.1.4. China Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.5.1.5. Japan Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.6. Japan Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
6.5.1.7. Japan Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
6.5.1.8. Japan Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.5.1.9. South Korea Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.10. South Korea Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
6.5.1.11. South Korea Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
6.5.1.12. South Korea Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.5.1.13. India Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.14. India Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
6.5.1.15. India Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
6.5.1.16. India Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.5.1.17. Southeast Asia Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.18. Southeast Asia Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
6.5.1.19. Southeast Asia Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
6.5.1.20. Southeast Asia Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.5.1.21. Rest of Asia Pacific Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.22. Rest of Asia Pacific Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
6.5.1.23. Rest of Asia Pacific Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
6.5.1.24. Rest of Asia Pacific Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Psoriasis Drugs Market Outlook, 2018 – 2031
7.1. Latin America Psoriasis Drugs Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Topical Psoriasis Drugs
7.1.1.2. Oral Psoriasis Drugs
7.1.1.3. Injectable Psoriasis Drugs
7.2. Latin America Psoriasis Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
7.2.1. Key Highlights
7.2.1.1. Interleukin Inhibitors
7.2.1.2. Corticosteroids
7.2.1.3. Anti-inflammatory
7.2.1.4. Tumor Necrosis Factor Inhibitors
7.3. Latin America Psoriasis Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Guttate Psoriasis
7.3.1.2. Inverse Psoriasis
7.3.1.3. Pustular Psoriasis
7.3.1.4. Erythrodermic Psoriasis
7.3.1.5. Plaque Psoriasis
7.4. Latin America Psoriasis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Hospital Pharmacies
7.4.1.2. Retail Pharmacies
7.4.1.3. e-Commerce
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Psoriasis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
7.5.1.2. Brazil Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
7.5.1.3. Brazil Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
7.5.1.4. Brazil Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.5.1.5. Mexico Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
7.5.1.6. Mexico Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
7.5.1.7. Mexico Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
7.5.1.8. Mexico Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.5.1.9. Argentina Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
7.5.1.10. Argentina Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
7.5.1.11. Argentina Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
7.5.1.12. Argentina Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.5.1.13. Rest of Latin America Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
7.5.1.14. Rest of Latin America Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
7.5.1.15. Rest of Latin America Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
7.5.1.16. Rest of Latin America Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Psoriasis Drugs Market Outlook, 2018 – 2031
8.1. Middle East & Africa Psoriasis Drugs Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Topical Psoriasis Drugs
8.1.1.2. Oral Psoriasis Drugs
8.1.1.3. Injectable Psoriasis Drugs
8.2. Middle East & Africa Psoriasis Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Interleukin Inhibitors
8.2.1.2. Corticosteroids
8.2.1.3. Anti-inflammatory
8.2.1.4. Tumor Necrosis Factor Inhibitors
8.3. Middle East & Africa Psoriasis Drugs Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Guttate Psoriasis
8.3.1.2. Inverse Psoriasis
8.3.1.3. Pustular Psoriasis
8.3.1.4. Erythrodermic Psoriasis
8.3.1.5. Plaque Psoriasis
8.4. Middle East & Africa Psoriasis Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. Hospital Pharmacies
8.4.1.2. Retail Pharmacies
8.4.1.3. e-Commerce
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Psoriasis Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
8.5.1. Key Highlights
8.5.1.1. GCC Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.2. GCC Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
8.5.1.3. GCC Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
8.5.1.4. GCC Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.5.1.5. South Africa Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.6. South Africa Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
8.5.1.7. South Africa Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
8.5.1.8. South Africa Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.5.1.9. Egypt Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.10. Egypt Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
8.5.1.11. Egypt Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
8.5.1.12. Egypt Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.5.1.13. Nigeria Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.14. Nigeria Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
8.5.1.15. Nigeria Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
8.5.1.16. Nigeria Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.5.1.17. Rest of Middle East & Africa Psoriasis Drugs Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.18. Rest of Middle East & Africa Psoriasis Drugs Market by Drug Class, Value (US$ Bn), 2018 – 2031
8.5.1.19. Rest of Middle East & Africa Psoriasis Drugs Market by Indication, Value (US$ Bn), 2018 – 2031
8.5.1.20. Rest of Middle East & Africa Psoriasis Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product vs Drug Class Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Janssen Biotech, Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Novartis International Ltd.
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Amgen Inc.
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Pfizer Inc.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Takeda Pharmaceutical Company Ltd.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Merck & Co, Inc.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Abb Vie Inc.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Eli Lilly and Company
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Boehringer Ingelheim GmbH
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Sun Pharmaceutical Industries Ltd.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings